孟德尔随机化
生命银行
乳腺癌
遗传关联
生物
全基因组关联研究
肿瘤科
蛋白质组
疾病
生物信息学
癌症
蛋白质组学
医学
遗传学
数量性状位点
队列
基因
内科学
孟德尔遗传
血液蛋白质类
计算生物学
特质
遗传变异
等位基因
血浆水平
定量蛋白质组学
候选基因
队列研究
单核苷酸多态性
基因型
作者
Xueyao Wu,Devika Godbole,Jacob Williams,Jayati Sharma,Jiyeon Choi,Zhonghua Liu,Peter L. Kraft,Haoyu Zhang
标识
DOI:10.64898/2026.05.04.26352055
摘要
Abstract Background The plasma proteome may help connect inherited breast cancer susceptibility to biologically interpretable and potentially actionable pathways, but proteome-wide evidence across ancestries remains limited. Methods We conducted proteome-wide Mendelian randomization (MR) analyses of breast cancer risk using cis -protein quantitative trait loci for 1,962 distinct plasma proteins from 34,557 European-ancestry participants in the UK Biobank Pharma Proteomics Project. Breast cancer genome-wide association studies included 156,901 cases and 204,634 controls of European, East Asian, and African ancestries. Ancestry-specific MR estimates were combined by fixed-effects meta-analysis. Candidate proteins were further evaluated through subtype-specific and reverse-direction MR analyses, statistical colocalization, replication in independent European and East Asian proteomic datasets, and analyses of associations between protein polygenic scores and breast cancer status in All of Us. Results Twelve proteins achieved Bonferroni significance in the cross-ancestry meta-analysis ( P < 0.05/1,971 tests), including eight previously reported proteins and four newly prioritized by MR. DNPH1 showed cross-ancestry heterogeneity, while CASP8, RALB, and USP28 showed cross-subtype heterogeneity after accounting for shared controls (all P < 0.05/12). Complementary support varied: six candidates showed strong colocalization (PPH4 ≥ 0.80); four replicated with a consistent direction and nominal significance in deCODE, two in the Japan COVID-19 Task Force, and four in All of Us (all P < 0.05). The strongest cumulative support was observed for LRRC25, PARK7, and LRRC37A2. Conclusions These findings prioritize circulating protein candidates for mechanistic, prevention-oriented, and translational follow-up in breast cancer, while underscoring the need for larger ancestrally diverse proteomic resources to support equitable target and biomarker discovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI